SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
COMMISSION FILE NO.: 0-53600
Date of Report
(Date of earliest event reported: October 29, 2012
CHINA YCT INTERNATIONAL GROUP, INC.
(Exact name of registrant as specified in
|(State of other jurisdiction of
|incorporation or organization
c/o Shandong Spring Pharmaceutical Co.,
Ltd Economic Development Zone
Gucheng Road Sichui County Shandong Province
|(Address of principal executive offices)
(Registrant’s telephone number including
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive
China YCT International
Group, Inc. (“CYIG”) entered into a termination agreement (the “Termination Agreement”)
as of October 29, 2012, with L.Y. Research Corporation (“LY Research”, together, the “Parties”), to terminate
a purchase agreement between the Parties entered in February 2011, as amended as of August 15, 2011 and October 21, 2011 (the “Purchase
On February 24 2011,
the Parties entered into the Purchase Agreement, which provided, in part, for the transfer of LY Research to CYIG of US patent
No. 6,475,531 B1, titled “Safe Botanical Drug for Treatment and Prevention of Influenza and Increasing Immune Function”
(the “Patent”), in consideration for the issuance of 44,254,952 shares of common stock of CYIG (the “Shares”),
as reported on our Current Report on Form 8-K and filed with the Securities and Exchange Commission on March 3, 2011.
On March 11,
2011, CYIG delivered the Shares to a designee of LY Research in consideration for the assignment of Patent from L.Y. Biotech
Limited, a wholly-owned subsidiary of LY Research on January 25, 2011, as reported on our Current Report on Form 8-K and
filed with the Securities and Exchange Commission on August 26, 2011.
On October 21,
2011, the Parties entered into an amendment to the Purchase Agreement, as reported on our Current Report on Form 8-K and
filed with the Securities and Exchange Commission on October 24, 2011. Pursuant to the Amendment Agreement, in the event
that certain conditions were not fulfilled on or before October 21, 2012, the Patent was to be returned to LYHK and the
Shares were to be returned to CYIG, and the Purchase Agreement, as amended, was to be cancelled and of no further force or
The abovementioned conditions were not fulfilled as of October 21, 2012. Therefore, the Parties entered into the Termination Agreement
to formally terminate the Purchase Agreement, and return the Patent and the Shares to LY Research and CYIG, respectively.
All of the respective
rights and obligations between the Parties existing or arising under the Purchase Agreement were cancelled and rendered null
and void, upon (1) the transfer of the Shares to CYIG and (2) the recording of the assignment of the Patent from CYIG
to L.Y. Biotech Limited with the United States Patent and Trademark Office on November 21, 2012.
A copy of the Termination
Agreement is attached hereto as Exhibit 10.1 and is incorporated herein by reference.
Item 9.01 Financial Statements
Termination Agreement, dated as
of October 29, 2012, by China YCT International Group, Inc. and L.Y. Research Corporation.
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
||China YCT International Group, Inc.|
|Dated: January 15, 2013
||By: /s/ Yan Tinghe|
||Chief Executive Officer|